Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

Publisher: John Wiley & Sons Inc

E-ISSN: 1756-185x|21|2|422-430

ISSN: 1756-1841

Source: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol.21, Iss.2, 2018-02, pp. : 422-430

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content